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Summary
Function-blocking antibodies to VEGF receptors R1 and R2 were used to probe their roles in controlling angiogenesis in
a mouse model of pancreatic islet carcinogenesis. Inhibition of VEGFR2 but not VEGFR1 markedly disrupted angiogenic
switching, persistent angiogenesis, and initial tumor growth. In late-stage tumors, phenotypic resistance to VEGFR2
blockade emerged, as tumors regrew during treatment after an initial period of growth suppression. This resistance to
VEGF blockade involves reactivation of tumor angiogenesis, independent of VEGF and associated with hypoxia-mediated
induction of other proangiogenic factors, including members of the FGF family. These other proangiogenic signals are
functionally implicated in the revascularization and regrowth of tumors in the evasion phase, as FGF blockade impairs
progression in the face of VEGF inhibition.S I G N I F I C A N C E
Numerous clinical trials are testing the efficacy of anti-VEGF/VEGF receptor therapies for various cancers. Several phase III trials
have provided evidence that anti-VEGF therapy, alone or in combination with chemotherapy, is efficacious and produces a transi-
tory stable disease followed by progression in several types of cancer. Here, we describe a mouse model of cancer wherein VEGFR2
inhibition also produces a period of stable disease followed by progression. We show that phenotypic resistance emerges to anti-
VEGFR2 therapy, which may explain the inevitable progression; this resistance involves vascular regrowth in a VEGF-independent
second wave of angiogenesis, mediated in part by proangiogenic ligands of the FGF family. Counteracting such mechanisms of
resistance by multitargeting alternative proangiogenic signaling circuits may improve efficacy of antiangiogenic therapies.Introduction
Tumor angiogenesis is regulated by a balance of pro- and anti-
angiogenic molecules, and when the balance shifts in favor of
angiogenesis inducers, an angiogenic switch activates the nor-
mally quiescent vasculature to develop new blood vessels (Ha-
nahan and Folkman, 1996), often concomitant with enlarge-
ment (dilation and microhemorrhaging) of the preexisting
vasculature (Ryschich et al., 2002). A prominent proangiogenic
signaling circuit involves the vascular endothelial growth factor
(VEGF) family, and in particular VEGF-A (Ferrara et al., 2003).
VEGF ligands bind to two transmembrane tyrosine kinase re-
ceptors expressed in blood vessel endothelial cells: VEGF re-
ceptor 1 (VEGFR1, Flt-1) and VEGF receptor 2 (VEGFR2, KDR
in humans, Flk1 in mice) (Shibuya, 2001). A number of clinical
trials are underway to test the utility of anti-VEGF or anti-
VEGFR therapies in a variety of cancers (Angiogenesis Inhibi-
tors in Clinical Trials, National Cancer Institute, http://www.
cancer.gov/clinicaltrials/developments/anti-angio-table/). A re-
cent phase III clinical trial demonstrated that bevacizumab
(Avastin), a humanized monoclonal antibody against VEGF-A,
in combination with conventional chemotherapy, increasedCANCER CELL : OCTOBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIERoverall survival by 5 months in colorectal cancer patients (Hur-
witz et al., 2004), leading to FDA approval. Much as for other
therapeutic strategies, apparent resistance to antiangiogenic
therapies has been described in clinical trials and in xenotrans-
plant tumor models (Kerbel et al., 2001; Miller et al., 2003,
2005); in particular, the development of nonresponsiveness to
an initially efficacious anti-VEGFR therapeutic regimen in a
xenotransplant model has been documented (Klement et al.,
2000), by an unknown mechanism.
Here, we use specific function-blocking monoclonal antibod-
ies to two VEGF receptors to probe their role in mediating and
sustaining angiogenesis and tumor growth in an endogenous
mouse model of islet cell carcinogenesis, where the functional
importance of VEGF signaling has been previously docu-
mented, via gene knockout of VEGF-A (Inoue et al., 2002) and
pharmacological inhibition of VEGF receptors with small mole-
cules (Bergers et al., 2000, 2003). The results presented herein
demonstrate that VEGFR2 is necessary for the angiogenic
switch and for sustaining tumor angiogenesis but in addition
document the emergence of phenotypic resistance to the
VEGFR2 blockade that allows for revascularization and re-
growth of treated tumors.INC. DOI 10.1016/j.ccr.2005.09.005 299
A R T I C L EResults
Immunodeficient islet cell carcinogenesis model
Our experimental design aimed to use rat monoclonal antibod-
ies that block ligand binding and consequent signaling by
VEGFR2 (MAb DC101) and VEGFR1 (MAb MF1) in the RIP-
Tag2 mouse model of islet cell carcinogenesis to probe recep-
tor functions and relative importance. To avoid the confounding
biases of neutralizing antibody responses, we developed an
immunodeficient variant of this prototypical model of cancer,
by rendering it homozygous deficient for the recombinase acti-
vator gene 1 (Rag1). Mice lacking Rag1 are unable to perform
V(D)J recombination of immunoglobulins and T cell receptor
genes during immune cell maturation, and thus are completely
deficient in adaptive immunity (Mombaerts et al., 1992). We
first characterized the tumorigenesis phenotype in RIP1-Tag2,
Rag1−/− mice, which revealed the same multistage tumor pro-
gression, with no apparent change in the histological pheno-
type of the tumors (Figure S1 in the Supplemental Data avail-
able with this article online). At end stage (13.5 weeks of age),
the immunodeficient animals showed similar tumor burden
(102 ± 23 mm3 compared to 110 ± 36 mm3 in immunocompe-
tent controls), similar tumor number (7 ± 2 tumors in immuno-
deficient animals compared to 8 ± 4 in immunocompetent con-
trols), and no change in the inflammatory infiltration of innate
immune cells, such as macrophages and granulocytes (Figure
S1 and data not shown). In contrast to the characteristic pres-
ence of macrophages and neutrophils in premalignant and ma-
lignant lesions, infiltration of mature B or T cells in the tumors
is not evident in the wild-type (immunocompetent) RIP1-Tag2
mice (unpublished data), and indeed RIP-Tag2 mice are evi-
dently self tolerant of their tumors (Adams et al., 1987; Joli-
coeur et al., 1994). The current analysis of the RIP1-Tag2,
Rag1−/− mice extends upon these previous studies, demon-
strating that mature B and T lymphocytes cannot be factors
in pancreatic islet tumorigenesis in RIP-Tag2 mice, either as
enhancers or antagonists, since their absence neither attenu-
ates nor accelerates tumorigenesis, in contrast, for example,
to mouse models of skin cancer and cervical cancer, where the
adaptive immune system either promotes (Daniel et al., 2003;
de Visser et al., 2005) or antagonizes (Daniel et al., 2005) tu-
morigenesis.
VEGFR2 blockade impairs angiogenesis
and tumorigenesis
The well-documented and relatively synchronous angiogenic
switching and multistage tumorigenesis in the RIP-Tag2 mouse
model of cancer allows for testing experimental therapies in
three “trial designs” that variously (1) assess effects on angio-
genic switching in progenitor lesions (prevention trial), (2) score
the explosive growth of nascent solid tumors (intervention trial),
or (3) ask whether tumor burden can be reduced or stabilized
concomitant with life span extension (regression trial) (Bergers
et al., 1999, 2000, 2003).
To evaluate the effects of VEGFR-blocking antibodies on the
angiogenic switch that first activates angiogenesis, we initiated
treatment of animals at 5 weeks of age (before the angiogenic
switch) and continued treatment for 3 weeks. While in mock-
treated animals the angiogenic switch resulted in hypervascu-
larized “red islets” with a dilated, microhemorrhaging vascula-
ture, VEGFR2 blockade produced a significant decrease in300angiogenesis and abolished the appearance of red islets (Fig-
ure 1A). In contrast, VEGFR1 blockade did not have a discerni-
ble effect. Histological analysis showed that VEGFR2-blocking
treatment significantly reduced vessel density, as shown by
systemic perfusion with a fluorescently labeled tomato lectin,
and impaired the characteristic microhemorrhaging as seen by
accumulation of erythrocytes inside the islets (previously de-
scribed as blood islands) (Figure 1B). We next asked whether
simultaneous blockade of VEGFR1 and -2 would further inhibit
angiogenesis above and beyond VEGFR2 inhibition alone. The
data show that blocking both receptors did not significantly
improve upon the antiangiogenic effects of VEGFR2 blockage
(Figure 1). These results are consistent with the well-estab-
lished importance of VEGF as a proangiogenic and vascular
permeability factor and reveal that VEGFR2 but not VEGFR1 is
crucial for the angiogenic switch in this tumor model. Given
previous work demonstrating that infiltrating inflammatory cellsFigure 1. Antibody blockade of VEGFR2 but not VEGFR1 impairs angiogen-
esis in pancreatic islet dysplasias, decreasing vessel density and microhem-
orrhaging
A: Quantification of number of angiogenic “red” islets per animal in the
different arms of treatment: control IgG, VEGFR2-blocking antibody,
VEGFR1-blocking antibody, and the combination of both VEGFR-blocking
antibodies. Averages of number of angiogenic islets per animal in cohorts
of eight to ten mice per arm are shown with their respective standard
deviation bars. *Statistically significant using Mann-Whitney test (p < 0.02)
when compared to control group.
B: Visualization of the vessels and histologic analysis of the microhemor-
rhaging in the treated and nontreated islet dysplasias. Vessels were la-
beled by i.v. perfusion of FITC-conjugated tomato lectin (green) followed
by DAPI counterstaining (blue), and neoplastic islets are delineated with a
white dotted line; hematoxylin and eosin (H&E) staining shows the micro-
hemorrhaged erythrocytes that have markedly accumulated in the core
of the islets, or not in the case of the anti-VEGFR2-treated animals. Repre-
sentative images are shown from an analysis of five sections per animal
from a minimum of five mice per group; scale bar, 50 m.CANCER CELL : OCTOBER 2005
A R T I C L Eare critical in supplying matrix metalloproteinases necessary to
trigger the angiogenic switch (Bergers et al., 2000), and the
report that certain inflammatory cells (i.e., macrophages) can
utilize the VEGF/VEGFR1 pathway for chemotaxis (Sawano et
al., 2001), we asked if VEGFR1 blockade was affecting the
mobilization and infiltration of these cells into the tumors.
Immunostaining with several macrophage markers indicated
that macrophage infiltration was not affected by blocking
VEGFR1, suggesting that other signaling pathways mediate the
recruitment of these cells into the islet tumors (data not
shown).
Given that VEGFR1 is expressed in both the premalignant
and tumor stages in this model (Christofori et al., 1995; and
data not shown), the marked ineffectiveness of the VEGFR1
antibody in all of our experiments led us to reconfirm its func-
tional activity. We tested the functional activity of MF1 in block-
ing VEGFR1 function in a previously validated in vivo assay
where VEGFR1 is demonstrably important (Passaniti et al.,
1992). In this assay, we treated animals with implanted subcu-
taneous matrigel plugs with the same dosage regimen of
VEGFR1-blocking antibody used in RIP-Tag2 animals, assess-
ing neovascularization of the VEGF-containing plug. The re-
sults showed that MF1 was active and able to block VEGFR1
function in vivo in the same dosage regimen (Figure S2), con-
sistent with a previous study (Luttun et al., 2002).
To evaluate the effects of the selective VEGFR1/2-blocking
antibodies on tumor formation and tumor growth subsequent
to the angiogenic switch, we initiated treatment in 10-week-old
animals, before the appearance of tumors, and continued the
treatment until 13.5 weeks of age, when end-stage tumors are
present. In this regimen, VEGFR2 blockade produced a signifi-
cant impairment of tumor formation, while blockade of
VEGFR1 had no effect (Figure 2A). Treatment with VEGFR2-
blocking antibodies significantly reduced the accumulated tu-
mor burden per animal (by 50%). The impaired tumor growth
was associated with clear histopathological differences in the
treated tumors, which evidenced marked decreases in vessel
density, vascular dilation, and permeability/microhemorrhaging
(Figure 2B). In contrast, VEGFR1 blockade with MF1 had no
effect (Figure 2A and data not shown). Notably, there was a
proportional decrease in tumor burden compared to vessel
density and vascular permeability in response to anti-VEGFR2
(Figures 2A and 2B), suggesting a causal link between these
parameters. We asked whether simultaneous blockade of
VEGFR1 and VEGFR2 would further inhibit angiogenesis and
tumor growth compared to VEGFR2 inhibition alone. Blocking
both receptors did not significantly improve upon the antian-
giogenic and antitumor effects of VEGFR2 inhibition alone (Fig-
ure 2 and data not shown).
Surprisingly, although the tumors were smaller in the mice
receiving the VEGFR2-blocking treatment, the tumors had a
significantly more invasive and malignant phenotype; most had
wide fronts of invasion into the surrounding acinar tissue (Fig-
ure 2C). This more invasive phenotype was even more striking
following immunostaining for the tumor’s collagenous capsule
with collagen I antibody. As shown in Figure 2C, mock-treated
tumors had a thick collagenous capsule that delineated them
from the surrounding acinar tissue, while the anti-VEGFR2-
treated tumors had a much thinner capsule with areas of
breakage or completely absent capsule. Increased invasive-
ness consequent to antiangiogenic therapies, including kinaseCANCER CELL : OCTOBER 2005Figure 2. VEGFR2-blocking antibody treatment selectively inhibits tumori-
genesis, with decreased vessel density and vascular permeability
A: Total tumor burden per animal is plotted for the different treatment
arms, each involving cohorts of eight to ten mice per group, with their
respective standard deviation bars. *Statistically significant using Mann-
Whitney test (p < 0.02) when compared to control group.
B: Quantification of intratumoral vessel density (white bars, left axis) and
vascular permeability analysis by Miles assay (black bars, right axis) with
their standard deviation bars. *Statistically significant differences were
found between VEGFR2-blocking treatment and control cohorts in both
analyses using the Mann-Whitney test (p < 0.02).
C: Histological images of tumors by H&E staining, and by collagen I immu-
nohistochemistry to visualize the tumor capsule (brown). Representative
images are shown from an analysis of five sections per animal from a mini-
mum of five mice per group. T, tumor; Ac, surrounding acinar tissue; scale
bar, 50 m. Tumors treated with anti-R1 were similar to controls by all cri-
teria, and the combination anti-R1 + R2 treatment was comparable to
anti-R2 alone (data not shown).inhibitors targeting VEGF receptors, has been observed in pre-
vious studies in this model (Bergers et al., 1999, 2000), as well
as in other models of cancer (Pennacchietti et al., 2003;
Steeg, 2003).
Surprising regrowth of established tumors
under VEGFR2-blocking treatment
To evaluate the capability of the VEGFR-blocking antibodies to
stabilize or regress late-stage tumors and extend life span, we
initiated treatment on 12-week-old animals, when there is al-301
A R T I C L Eready a significant accumulated tumor burden (60 mm3). Ini-
tially, cohorts of eight to ten mice were treated for 10 days
beginning at 12 weeks of age, until the mock-treated controls
had reached end stage (13.5 weeks). As shown in Figure 3A,
mock-treated animals approximately doubled their tumor bur-
den during this time of treatment, whereas VEGFR2-blocking
treatment stabilized the tumor burden, producing a 50% reduc-
tion in accumulated tumor burden after the 10 days of treat-
ment compared to the control cohort. Once again, VEGFR1
blockade did not show any difference compared to controls,
and the combination of anti-VEGFR1 and anti-VEGFR2 did not
further enhance the VEGFR2-blocking antibody’s effects (Fig-
ure 3A). Fluorescent-lectin perfusion of the tumor vasculature
revealed a significantly reduced vessel density in the VEGFR2-
treated animals with stable tumor burden, in comparison with
the other cohorts where tumors grew during this period (Figure
3B and data not shown). The data indicate that, during this
short time of treatment, VEGFR2 blockade was targeting the
angiogenic tumor vasculature and consequently restraining tu-
mor growth.
We next sought to extend the treatment for a total period of
4 weeks, well after the control animals died of their tumor bur-
den, in a standard regression trial (according to Bergers et al.,
1999, 2003). In this regimen, VEGFR2 blockade produced a
modest survival benefit, in that all treated mice lived to the
defined endpoint of +4 weeks. Analysis of tumor burden, how-
ever, revealed that the initial “stable disease” phase was fol-
lowed by progression, a surprising regrowth of the anti-
VEGFR2-treated tumors (Figure 3A). This regrowth phase led
to an accumulated tumor burden per animal that was compara-
ble to that found in end-stage control animals. Again, there was
no added benefit from combining the anti-VEGFR1 and anti-
VEGFR2. In both cohorts (blocking VEGFR2 only, or R1 + R2),
the tumors that grew during the extended treatment showed a
more invasive and malignant phenotype (data not shown). In
regard to the vasculature, two distinctive classes were appar-
ent in the regrowth phase, as revealed by vascular perfusion.
The predominant class had increased vascular density and the
biomarkers of angiogenesis (dilated vessels, microhemorrhag-
ing), comparable to untreated tumors, and were markedly dis-
tinct from the tumors in the transitory stable disease phase (at
+10 days) (compare Figure 3Bd with Figure 3Be). Additionally,
we observed a rare class of tumors that did not evidence an
increased vascular density but rather contained small vessels
with less branching at their periphery (marked by arrowheads
in Figure 3Bf). These more “normal” vessels are typical of those
observed in the normal exocrine pancreas. A similar histologi-
cal pattern of vascularization has been reported in other tumor
models as well as in certain human tumors and has been
termed “vessel cooption” of the adjacent “normal” vasculature
by neoplasms (Holash et al., 1999; Leenders et al., 2004; Pez-
zella et al., 1997). Rebounding tumors with apparent coopted
vessels and no evident angiogenesis were rare, and thus have
not been included in the subsequent molecular analysis of the
revascularization. To quantitatively assess the extent of revas-
cularization that occurred in the majority class of tumors in the
relapse phase, vessel density analysis was performed at vari-
ous time points during the anti-VEGFR2-blocking treatment. As
shown in Figure 3C, the short 10 day treatment produced a
statistically significant decrease in vessel density, whereas
upon extending the treatment for a total of 4 weeks, the vessel302Figure 3. VEGFR2 blockade transiently stops tumor growth and decreases
vascularity, followed by tumor progression, reinduction of angiogenesis,
and reestablishment of the tumor vasculature
A: Quantification of overall tumor burden plotted as average and stan-
dard deviation per animal at the time of initiation of treatment (t = 0; black
bar) and after treatment for 10 days (gray bars) and for 4 weeks of age
(white bars) for the different treatment arms. Averages from cohorts of
eight to ten mice per group are plotted with their respective standard
deviation bars. *Statistically significant differences using Mann-Whitney test
(p < 0.02) compared to age-matched controls.
B: Vessel labeling by FITC-conjugated tomato lectin (green) and DAPI
counterstain of nuclei (blue) from nontreated animals (Ba); animals that
received mock treatment for 10 days (Bb); or animals that were treated
with anti-VEGFR2 antibodies for 3 days (Bc), for 10 days (Bd), or for 4 weeks
showing revascularization (Be), or for 4 weeks showing cooption (Bf).
Images shown are representative of a total of five sections per animal from
a minimum of five mice per group analyzed. Tumors are marked as “T.”
White arrowheads in Bf point to a normal vessel that runs along the tissue
boundary and is possibly coopted by the growing tumor. Scale bar, 50 m.
C: Quantification of the vessel density in the anti-VEGFR2-treated tumors
at 3 days, 10 days, and 4 weeks of treatment compared to t = 0 controls.
Averages from a minimum of eight images corresponding to four to five
mice per time point are plotted with their respective standard deviation
bars. *Statistically significant decrease compared to controls using the
Mann-Whitney test (p < 0.01).CANCER CELL : OCTOBER 2005
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treated tumors. These results suggest that, concomitant with
the reinitiation of tumor growth in the extended treatment, an-
giogenesis is reactivated and the vessel density is reestab-
lished. Thus, the initial vascular disruption caused by the
VEGFR2-blocking treatment is evidently followed by a second
wave of angiogenesis in most tumors that is capable of rees-
tablishing a typically dense and aberrant tumor vasculature.
This result suggests the emergence of resistance to or evasion
of the VEGF blockage by the tumor endothelium.
To address one possible explanation, that the blocking anti-
body was losing effectiveness in the long-term treatment, we
analyzed the tumors from the extended anti-VEGFR2 treatment
for phenotypic and molecular markers of the VEGFR2 inhibi-
tion, such as microhemorrhaging, vascular permeability, and
the phosphorylation status of VEGFR2. While the control
mock-treated tumors showed the apparent microhemorrhaging
and redness typical of the islet tumors in these mice, the long-
term anti-VEGFR2-treated tumors still showed a white non-
hemorrhaging phenotype (Figure 4A), which is consistent with
our results in earlier-stage intervention and short regression tri-
als (data not shown) and is in accordance with the inhibition of
VEGFR2’s vascular permeability function. Furthermore, to as-
sess the molecular efficacy of the anti-VEGFR2 blockade of
receptor signaling, the phosphorylation status of VEGFR2 in
the treated tumors was determined using antibodies that are
diagnostic of VEGFR2 activation, by recognizing a phosphory-
lation site in the VEGFR2 kinase domain, of tyrosine 951 (Y951)
(Dougher-Vermazen et al., 1994; Matsumoto et al., 2005). As
shown in Figure 4B, VEGFR2 phosphorylation of Y951 was
readily detected in tumors from control, mock-treated animals
by Western blotting, but not in the 10 day responding or the 4
week rebounding tumors being treated with anti-VEGFR2 anti-
body. Quantification of phospho-VEGFR2 in treated tumors
compared to controls showed a >90% reduction in detectable
receptor phosphorylation in tumors from the anti-VEGFR2-
treated animals, which is statistically significant (p > 0.02) using
the Mann-Whitney U test. Thus, both the maintained lack of
microhemorrhaging and redness and the molecular analysis of
VEGFR2 phosphorylation demonstrate that the VEGFR2-
blocking antibody retains its functional activity in inhibiting the
signaling by its target receptor throughout the 4 weeks of treat-
ment, despite its only transitory capability to stop tumor growth
and reduce tumor vascularity.
Short-term VEGFR2 blockade triggers hypoxia
and upregulation of other proangiogenic factors
To begin investigating the mechanism of this apparent evasion
of VEGFR2 blockade, we evaluated possible changes in the
microenvironment of the tumors that could be triggered by the
VEGFR2 blockade. One possible factor was hypoxia, as it has
been described that a variety of angiogenesis inhibitors can
trigger hypoxia in treated tumors (Yu et al., 2002). Indeed, we
found that short-term anti-VEGFR2-treated tumors had clear
areas of hypoxia, as detected by formation of pimonidazole
adducts and by detection of the hypoxia-regulated transcrip-
tion factor HIF-1α, effects that were undetectable in the un-
treated tumors (Figure 5A and data not shown). Surprisingly,
the acute hypoxia visualized by pimonidazole was transitory,
being detectable only in the tumors after the short-term (10
day) anti-VEGFR2 treatment, but not in the longer-term (4CANCER CELL : OCTOBER 2005Figure 4. Continuing molecular efficacy of the VEGFR2-blocking antibody
during the phenotypic evasion phase
A: Gross pathology images of the excised pancreas and spleen from ani-
mals after 4 weeks of treatment showing the “red” vascularized and hem-
orrhaging phenotype of the control tumors, and lack thereof in the 4 week
anti-VEGFR2-treated tumors due to continued blocking of VEGFR2.
B: VEGFR2 phosphorylation status detected by Western blot from whole
tumors using an antibody that specifically recognizes phospho-Y951 of
VEGFR2. Phosphorylation in Y951 was detected in tumors from mock-
treated animals (Control) but is absent in the tumors treated with anti-
VEGFR2 for 10 days or 4 weeks. Quantification of phospho-Y951-VEGFR2 in
treated tumors compared to controls is shown as a bar graph of average
band intensity with standard deviation bars. Both short and long treatment
with anti-VEGFR2 antibody show a >90% reduction in detectable receptor
phosphorylation, which is statistically significant (p > 0.01) using the Mann-
Whitney U test.week) treatment; we infer that the revascularization (or in rare
cases normal vessel cooption) had ameliorated the acute
hypoxia.
Hypoxia is a known inducer of angiogenic responses in a
wide variety of tumor types, involving induction of gene expres-
sion, via the HIF transcription factor, of various proangiogenic
factors, including VEGF and FGFs (reviewed in Pugh and Rat-
cliffe, 2003). This knowledge motivated a candidate gene ex-
pression profiling analysis, by Q-RT-PCR (TaqMan) on mRNA
from total tumors, to assess possible changes in a set of pro-
angiogenic factors, including ones previously implicated in
RIP-Tag2 angiogenesis, namely FGFs and Ephrins (Brantley et
al., 2002; Cheng et al., 2003; Compagni et al., 2000). This
analysis revealed that several members of the FGF, Ephrin, and
Angiopoietin families of proangiogenic factors were upreg-
ulated in the context of VEGFR2-blocking treatment when
compared to mock-treated controls (Figure 5B). In particular,303
A R T I C L EFigure 5. Short-term VEGFR2 blockade promotes hypoxia and a change in
the expression of proangiogenic factors in tumors
A: Hypoxia in islet tumors was detected by the formation of pimonidazole
adducts as described in the Experimental Procedures. Immunodetection
of pimonidazole adducts is shown in red, and nuclei counterstained with
DAPI are shown in blue. Images shown are representative of an analysis of
a minimum of five sections from each of three animals at t = 0, t = 10 days,
or t = 4 weeks of anti-VEGFR2-blocking treatment; scale bar, 50 m.
B: Quantitative RT-PCR expression analysis of different proangiogenic fac-
tors and their primary receptors in total tumors from the anti-VEGFR2-
treated tumors compared to control tumors. Bar graph shows fold upreg-
ulation of each molecule in VEGFR2-blocking treatment comparing to
controls. Values represent averages and standard deviations of two inde-
pendent experiments, and the red dotted line represents a value of 1 (no
change of expression in treatment). The boxes underneath indicate the
presence (+) or absence (−) and relative abundance of each molecule’s
mRNA expression in FACS-sorted cell populations from the tumors (TC, tu-
mor cell compartment; EC, endothelial cell compartment) as determined
by quantitative RT-PCR.
C: Analysis of protein levels of different proangiogenic factors in total tu-
mors from the anti-VEGFR2-treated tumors compared to control tumors, by
Western blot (VEGF-164 and Angiopoietin-1) or by ELISA-based commer-
cial antibody array (total VEGF and FGF2). Bar graph shows fold upregula-
tion of each molecule’s protein levels in VEGFR2-blocking treatment com-
paring to controls. Values represent averages and standard deviations of
three to five tumors for each treatment arm from two independent experi-
ments, and the red dotted line represents a value of 1 (no change of
expression in treatment).304VEGF-A, several FGF family members, Ephrin-A1, and Angio-
poietin-1 all showed a significant induction, ranging from
1.5-fold to almost 3-fold in the anti-VEGFR2-treated tumors.
Expression of the receptors for these three families of proangi-
ogenic factors was not appreciably changed by the treatment
(Figure 5B). To determine whether these genes were being
upregulated in the tumor cells or in the endothelial cells, we
dissected tumors and separated the endothelial cell and tumor
cell populations by fluorescence-activated cell sorting (FACS),
as previously described (Bergers et al., 2003). Using mRNA
prepared from these two FACS-purified cell populations, we
evaluated the expression levels of the proangiogenic ligands
and found that most were upregulated in the tumor cell popula-
tion (VEGF-A, FGF1, FGF2, FGF7, FGF8, Ephrin-A1, and Angi-
opoietin-2) whereas a partially overlapping set was upregulated
in the tumor endothelial cells (FGF1, FGF2, Ephrin-A1, and An-
giopoietin-1 and -2) (Figure 5B). To substantiate the RNA analy-
sis, we also assessed several of these factors at the protein
level, using immunoblotting and an antibody array with an
ELISA-based quantitative readout. As shown in Figure 5C, pro-
tein levels of total VEGF, VEGF-164, FGF2, and Angiopoietin-1
were increased in the VEGFR2-blocking treatment when com-
pared to mock-treated controls, as revealed by the two com-
plementary assays, consistent with the RNA analysis. We also
assessed the relative expression of these angiogenic factors
after 4 weeks of treatment, when revascularization had oc-
curred. Interestingly, their expression remained elevated in the
anti-VEGFR2-treated tumors compared to mock-treated con-
trols (data not shown), despite the fact that acute hypoxia was
no longer detectable. Thus, some mechanism serves to sustain
elevated expression of these factors once activated by acute
hypoxia; one possibility is that low-level hypoxia not detectable
by pimonidazole persists in the rebounding tumors in the ab-
sence of VEGF signaling, maintaining elevated expression of
the upregulated angiogenic factors.
Seeking to substantiate the hypothesis that hypoxia was af-
fecting the tumor cells, triggering the observed changes in ex-
pression of these proangiogenic factors, we analyzed the re-
sponse of cultured islet tumor cells to hypoxia in vitro. When
the βTC3 cell line derived from RIP-Tag2 tumors (Efrat et al.,
1988) was cultured under hypoxic conditions (2% oxygen, 5%
CO2), VEGF-A, FGF2, and Ephrin-A1 mRNAs were upregu-
lated, from 1.5-fold to 2.5-fold (Figure 6). VEGF and FGF2 were
further analyzed at the protein level with the ELISA-based anti-
body array, and as shown in Figure 6, both were upregulated,
a result that was consistent with the mRNA results. FGF1 was
not induced by hypoxia in the cultured cells, in contrast to the
results in whole tumors or FACS-purified primary tumor cells
(compare Figure 5B and Figure 6). We suspect that these differ-
ences are consequent to the cell culture conditions and/or the
adaptation of the tumor cells to culture.
Blocking FGF signaling impairs the evasion
of VEGFR2 inhibition
Collectively, the data suggest that phenotypic resistance to ex-
tended VEGFR2-blocking treatment results from a hypoxia-
driven change in the repertoire of proangiogenic factors ex-
pressed, enabling a transition from primary dependence on
VEGF signaling to reliance instead on alternative angiogenic
factors. While the VEGF-A ligand is itself upregulated in the
treated tumors (and hypoxic tumor cell lines), it is evidently in-CANCER CELL : OCTOBER 2005
A R T I C L EFigure 6. Hypoxia induces increased expression of proangiogenic factors
in tumor-derived βTC cell lines
RIP-Tag2 tumor-derived cells (βTC3) were cultured in vitro under normoxic
(20% oxygen, 5% CO2) or hypoxic (2% oxygen, 5% CO2) conditions for 24
hr, and quantitative RT-PCR analysis (mRNA Expression) and protein level
analysis of several proangiogenic factors were performed as described in
the Experimental Procedures section. Results are plotted as fold change in
hypoxic versus normoxic culture conditions for each of the proangiogenic
factors noted. Values represent averages and standard deviations of two
independent experiments, and the red dotted line represents a value of 1
(no change of expression in treatment).effectual, due to the continuing blockade of VEGFR2 signaling
(evidenced by the suppression of VEGFR2 phosphorylation;
see Figures 4A and 4B). We postulated, therefore, that the hyp-
oxia-triggered upregulation of other proangiogenic factors was
the driving force in reactivating angiogenesis in the face of
VEGFR2 blockade. To test this hypothesis, we designed a two-
stage regression trial regimen, beginning with anti-VEGFR2-
blocking antibody treatment for 10 days. Then, at +10 days
(when efficacy of the monotherapy was maximal), we added on
a blockade of the proangiogenic FGFs, using an adenovirus-
delivered soluble form of FGFR2 (FGF-trap), seeking to inhibit
revascularization and tumor progression. The FGF-trap adeno-
virus has been previously reported to bind and block various
ligands of the FGF family, including FGF1, FGF3, FGF7, and
FGF10, thereby effectively inhibiting angiogenesis in vitro and
in vivo (Compagni et al., 2000). Indeed, adding the FGF-trap
treatment in the regrowth phase produced a significant de-
crease in tumor growth compared to anti-VEGFR2 alone (Fig-
ure 7A). This decrease in tumor burden was accompanied by
a decrease in angiogenesis that was observed as decreased
intratumoral vessel density (Figure 7B). Quantification of this
parameter revealed a 41% reduction of the vessel density in
the dual anti-VEGFR2 + FGF-trap combination treatment, as
compared to anti-VEGFR2 alone (p = 0.02, Mann-Whitney
test). Histological analysis by H&E staining of the dual-treated
tumors revealed a phenotype that was similar to that of tumors
treated only with anti-VEGFR2-blocking antibody: the tumors
were smaller but more locally invasive (data not shown). In
sum, the data functionally implicate proangiogenic FGF ligands
in the reestablishment of the vasculature and regrowth of tu-
mors that manifest phenotypic resistance, and demonstrate
that concomitant blockade of both VEGF and FGF signaling
serves to limit the evasive reinduction of angiogenesis and
consequent regrowth of the tumors. Although tumor burdenCANCER CELL : OCTOBER 2005Figure 7. Proangiogenic ligands from the FGF family are important for rees-
tablishing the vasculature and supporting regrowth of tumors
A: Quantification of overall tumor burden per animal for 10 days and 4
weeks of the different treatment groups, as noted. Averages from cohorts
of eight to ten mice are plotted with their respective standard deviation
bars. *Statistically significant differences using Mann-Whitney test (p < 0.02)
when comparing anti-VEGFR2 + FGF-trap combination to anti-VEGFR2
alone.
B: Vessel labeling by FITC-conjugated tomato lectin (green) and DAPI
counterstain of nuclei (blue) for the different time points and treatment
arms as noted. Images shown are representative of an analysis of a mini-
mum of five sections from each of eight animals from every treatment
group; scale bar, 50 m. Quantification of intratumoral vessel density re-
vealed a 41% reduction of the vessel density in the dual anti-VEGFR2 +
FGF-trap combination treatment, as compared to anti-VEGFR2 alone (p =
0.02, Mann-Whitney test).and vessel density are significantly decreased in this double-
targeted anti-VEGFR2 and FGF-trap treatment, both parame-
ters are still slightly higher than the phase of maximal response
to single VEGFR2 blockade (in Figure 7, compare anti-R2 at 10
days to anti-R2 + FGF-trap at 4 weeks), suggesting that other
proangiogenic factors, e.g., Ephrins or Angiopoietins, could be
additionally stimulating tumor angiogenesis and facilitating tu-
mor growth.
Discussion
The studies reported herein with function-blocking monoclonal
antibodies have revealed that VEGFR2 plays a critical role in
promoting and sustaining angiogenesis in pancreatic islet cell
tumors. The data further demonstrate that VEGFR2 blockade
is an effective antiangiogenic and antitumor agent, whose ef-
fects are associated with decreased vessel density, decreased
vascular permeability, and reduced microhemorrhaging. In
marked contrast, although VEGFR1 is expressed in the prema-
lignant and tumor stages in this model (Christofori et al., 1995;
and data not shown), blocking VEGFR1 did not affect tumor305
A R T I C L Eprogression or angiogenesis in any of the trials performed.
VEGFR1 has on the one hand been implicated by gene knock-
out studies as a nonsignaling “sink” or “depot” for VEGF ligand
(Hiratsuka et al., 1998). More recently, however, this receptor
has been implicated in other processes of potential importance
for tumorigenesis, including macrophage mobilization (Sawano
et al., 2001) and recruitment of hematopoietic stem cells to the
neovessels of tumors (Hattori et al., 2002; Rabbany et al.,
2003). In the RIP-Tag2 model of pancreatic islet carcinoma, in-
nate immune cells have been documented to play an important
role in supplying the tumor with metalloproteinases and other
matrix-degrading enzymes that trigger angiogenesis and tumor
progression (Bergers et al., 2000; Joyce et al., 2004, 2005). Our
results indicate that macrophage recruitment is not affected by
the blockade of VEGFR1 or VEGFR2 (data not shown), sug-
gesting that other signaling molecules are promoting the innate
immune infiltration. VEGFR1 has also been implicated in the
recruitment of bone marrow-derived hematopoietic stem cells
to the neovessels of tumors (Hattori et al., 2002; Rabbany et
al., 2003). Our data, which indicate that blocking VEGFR1 does
not alter the tumor progression or the angiogenic phenotype in
the course of pancreatic islet carcinogenesis, suggest that this
tumor type is not dependent on such hematopoietic precur-
sors, consistent with other studies in which we have failed to
document significant incorporation of marked bone marrow-
derived cells into tumor vasculature (D. McDonald and D.H.,
unpublished data).
Drug resistance by circumventing VEGF
receptor blockade
Although the VEGF-VEGFR2 signaling circuit is an increasingly
validated target in solid tumors, eventual progression of dis-
ease in the face of VEGF/VEGFR therapies has been described
in clinical trials and in mouse models of cancer (Broxterman et
al., 2003; Kerbel et al., 2001; Miller et al., 2003, 2005; Klement
et al., 2000). Our results of phenotypic resistance in extended
regression trials with the VEGFR2-blocking treatment are con-
sistent with these previous findings and further support the
existence of mechanisms for phenotypic resistance or escape
from the effects of anti-VEGFR treatment. Notably, we observe
a period of stable disease followed by progression, accompa-
nied by a significant life span extension. This pattern of tumor
stasis and then tumor growth is arguably analogous to the de-
layed time to progression seen in the clinical trials with bevaci-
zumab (Avastin) as monotherapy (Yang et al., 2003) or in com-
bination with chemotherapy (Hurwitz et al., 2004). Furthermore,
our results suggest a mechanism by which the tumors develop
the capability to begin regrowing in the face of VEGFR2 block-
ade with restoration of high blood vessel density. This escape
is not a failure in the VEGFR2 blockade, since the vessel micro-
hemorrhaging and VEGFR2-activating phosphorylation are
both comparably reduced at the short- and long-term treat-
ments. Rather, the data implicate hypoxia-triggered upregula-
tion other proangiogenic factors (FGFs and Ephrins) that re-
stimulate tumor angiogenesis in a VEGF-independent fashion,
as schematized in Figure 8. Indeed, our two-phase dual block-
ade of VEGFR2 and FGF ligands produced a significant inhibi-
tion of angiogenesis and tumor growth, demonstrating a role
for FGF ligands in the late-phase evasion of anti-VEGFR2
treatment.
While the proangiogenic FGFs and Ephrins have been pre-306Figure 8. Model of the early and late phases of response to anti-VEGFR2
therapy in the RIP-Tag2 islet carcinogenesis model
Differential effects are apparent in the early-stage versus late-stage anti-
VEGFR2 treatment. In the initial phase (left), VEGF is the main regulator of
angiogenesis (purple arrows), and the VEGFR2 blockade causes vascular
and tumoral regression (objective response). Nevertheless, it also causes
regions of hypoxia (black arrows) in the tumors that initiate the circumven-
tion phase. In this latter phase of circumvention (right), which produces
phenotypic resistance to VEGFR2 blockade, the tumor cells upregulate
expression of other proangiogenic factors, including FGFs (red arrows) that
are demonstrably important in this model for the observed reactivation of
angiogenesis. The result is reestablishment of the tumor vasculature and
progression to continuing tumor growth.viously implicated in RIP-Tag2 angiogenesis (Brantley et al.,
2002; Cheng et al., 2003; Compagni et al., 2000), they seem
to play a supporting role to VEGF in the early stages of islet
tumorigenesis. Both a tissue-specific gene knockout (Inoue et
al., 2002) and pharmacological inhibition of VEGFR signaling
with small molecule kinase inhibitors (Bergers et al., 2000,
2003) indicate that VEGF is crucial in the early stages of tumor
progression, for angiogenic switching, tumor formation, and
initial tumor growth. By contrast, VEGFR inhibition was equivo-
cal when used as monotherapy against late-stage tumors
(Bergers et al., 2003; and this study). Collectively the data sug-
gest that these other proangiogenic circuits primarily serve to
enhance the critical VEGFR signal in early-stage lesions,
whereas in later stages of progression, they can either enhance
VEGF signaling or indeed substitute for it. Thus, in the face of
VEGFR2 inhibition, other proangiogenic factors can circumvent
the blockade, to promote a new wave of angiogenesis and
tumor growth. Interestingly, analysis of the revascularized
VEGFR2-blocked tumors in the regrowth and progression
phase after 4 weeks of treatment showed that, although acute
hypoxia was no longer detectable with our assays, moderately
increased expression of the proangiogenic factors persisted
(data not shown). One attractive model, to be investigated in
future studies, is that subtle hypoxia persists in the tumors
whose growth and progression is supported by alternative tu-
mor angiogenesis factors, thereby maintaining their elevated
expression once activated in the acute hypoxic phase.
Translational implications
We show, in a two-stage regression trial regimen, that adding
an inhibitor of the circumventing FGF signal when the VEGF
therapy is beginning to fail can significantly retard reinitiation
of angiogenesis and tumor progression. To date, human clinical
trials that selectively target VEGF or VEGFRs are merely delay-
ing time to progression after a period of stable disease, thusCANCER CELL : OCTOBER 2005
A R T I C L Eaffording a modest survival advantage (e.g., Hurwitz et al.,
2004), much like that seen in this mouse model of cancer. We
imagine that similar mechanisms are operative in such human
tumors whereby alternative proangiogenic signaling circuits are
upregulated and come to supplant to varying degrees the de-
pendence on VEGF. It will be of considerable interest to analyze
biopsies from patients whose tumors are progressing in the
face of VEGF/VEGFR blockade, to see whether this means of
evasion is similarly operative. If so, we foresee two possible
means to interfere with this phenotypic resistance to VEGF/
VEGFR therapy in human cancer. First, inhibitors of the circum-
venting proangiogenic factors could be introduced into the trial
regimens at the time of progression. Alternatively, multitargeted
inhibitors, or cocktails of specific inhibitors (e.g., of VEGF, FGF,
and likely Ephrins, etc.) could be used initially, seeking to keep
the angiogenic switch shut off, avoiding the secondary wave
of angiogenesis consequent to hypoxia-induced upregulation
of alternative proangiogenic growth factors in the face of VEGF
signaling inhibition. Much as knowledge of classical drug resis-
tance mechanisms is providing rational inroads to finesse
them, we suggest that insight into phenotypic resistance to
VEGF/VEGFR-targeted therapy will afford means to develop
antiangiogenic therapies with enduring efficacy.
Experimental procedures
Generation of RIP-Tag2;Rag1 knockout
The generation and characterization of the single transgenic RIP-Tag2 mice
(Hanahan, 1985) and the Rag1 knockout (Mombaerts et al., 1992) have
been previously reported. RIP-Tag2 inbred in C57-Bl6-J was crossed to
Rag1tm1Mom C57-Bl6-J from Jackson Labs. As the two genes sit in close
proximity in mouse chromosome 2, the screening of more than 100 pups
was necessary until a recombinant chromosome RIP-Tag2;Rag1 null was
obtained. This “founder” animal was backcrossed to Rag1 null animals to
obtain RIP-Tag2;Rag1 null homozygotes. All housing, care, and experi-
ments with mice were performed in accordance with the University of Cali-
fornia, San Francisco (UCSF) institutional and national guidelines and regu-
lations governing the care of laboratory mice.
Therapeutic antibody treatment
Rat monoclonal function-blocking antibodies against VEGFR1 (MF1) and
VEGFR2 (DC101) were obtained from ImClone Systems Incorporated (New
York, NY). The dosage regimen used was 1 mg DC101 per mouse and 1.25
mg MF1 per mouse twice a week through intraperitoneal injection. Control
animals were treated with purified rat IgG (ChromPure rat IgG, Jackson
Immunoresearch) at a dose of 1.25 mg per mouse twice a week. Cohorts
of eight to ten mice were treated per each arm of the trial study, and each
trial was repeated at least once.
Standard methods
Standard techniques for quantitating angiogenic islets and tumors (Parangi
et al., 1996), assessing histopathology and vascular morphology (Inoue et
al., 2002; Bergers et al., 2003, Joyce et al., 2004) and vascular permeability
(Miles and Miles, 1952), isolating constituent cells from tumors (Bergers et
al., 2003), and the matrigel plug angiogenesis bioassay (Passaniti et al.,
1992), are presented in the Supplemental Data.
Protein analysis of tumors and βTC cell lines
Whole tumor samples or βTC3 cell line pellets were lysed in RIPA buffer
containing a cocktail of protease inhibitors (Leupeptin, Aprotinin, and
PMSF), followed by homogenization and clearing by centrifugation as de-
scribed elsewhere. Total protein (50 g) was resolved in SDS-PAGE gels,
transferred onto PVDF membranes, and analyzed by Western blotting using
the following antibodies: anti-VEGF Ab-3 (JH121, Neomarkers, Labvision
Corp.) and anti-Angiopoietin-1/4 (sc9360, Santa Cruz Biotech). Protein level
analysis was also performed using an ELISA-based commercial antibody
array (“Raybio Mouse Angiogenesis Ab-Array”; M0319801, RayBiotechCANCER CELL : OCTOBER 2005Inc.,) which allows for quantitative determination of protein levels of a vari-
ety of proangiogenic factors including total VEGF and FGF2. Hybridization
and detection were performed following manufacturer’s instructions using
500 g of tumor lysates or βTC3 cell lysates. Western blot immunodetection
of phospho-VEGFR2 was performed using a mouse anti-phospho-VEGFR2
Y951, clone 7H11 (#2467, Cell Signaling Technology) as described (Matsu-
moto et al., 2005) starting from 200 g of tumor lysates. For all the Western
blots and the antibody array, quantification of band or spot intensities was
performed using BioRad Quantity One software.
Hypoxia assays
Hypoxia in islet tumors was detected by the formation of pimonidazole ad-
ducts after the injection of pimonidazole hydrochloride compound into tu-
mor-bearing animals for 2 hr. Pancreas sections were immunostained to
detect pimonidazole adducts using Hypoxyprobe-1-Mab1 antibody (Hypo-
xyprobe kit, Chemicon) following the manufacturer’s instructions. For the
hypoxia in culture, RIP-Tag2 tumor cells were cultured under normoxic
(20% oxygen, 5% CO2) or hypoxic (2% oxygen, 5% CO2) conditions in a
three-gases hypoxic chamber for 24 hr rapidly followed by lysis and RNA
extraction (RNeasy, Qiagen) and TaqMan quantitative RT-PCR reaction as
previously described.
FGF-trap preparation and therapy
Adenovirus FGF-trap was developed and described previously (Compagni
et al., 2000), and preparation of high-titer adenovirus was subcontracted to
Vector Biolabs, Philadelphia, PA. Adenovirus FGF-trap was tested in vitro
for sFGFR2iiib production in HeLa cells and for FGF-driven proliferation
in HUVEC cells as described (Compagni et al., 2000). In vivo delivery to
RIP-Tag2 mice was performed in a one-time intravascular injection of
1–3 × 109 viral infective units per animal and checked for serum presence
of sFGFR2iiib protein by heparin-Sepharose immunoprecipitation, as de-
scribed in Compagni et al. (2000).
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures
and two supplemental figures and can be found with this article online at
http://www.cancercell.org/cgi/content/full/8/4/299/DC1/.
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